* Freedman, L., Cockburn, I. and Simcoe, T. (2015). The Economics of Reproducibility in Preclinical Research. PLOS Biology, 13(6), p.e1002165.
† Freedman et al. report figures for the US only. We have extrapolated their data to reflect the fact that the US accounts for 58% of global pharmaceutical R&D.
We exponentially increase the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments.
Curate the world's largest collection of data from life science experiments and reagent catalogs
Decode and organize the information with reagent-specific machine learning models
Provide rapid insights in a clear, easy-to-use interface with turnkey deployment across an enterprise
15 of the top 20 pharmaceutical companies in the world trust BenchSci, and it is used by over 31,000 scientists at 3,600 institutions worldwide
Companies using BenchSci save up to $6 million per year in hard costs alone**** Based on proprietary customer spend analysis. Depends on a number of factors, including a company’s total annual reagent spend and its waste ratio.
Researchers using BenchSci move faster, with less time searching for and validating reagents
In partnership with the world's leading scientific publishers
Over 80% of scientists say that BenchSci accelerates their work^^ On average from surveys conducted on hundreds of industry scientists across various therapeutic areas and geographies.
Proudly funded by F-Prime and Gradient Ventures, Google’s AI fund